Fas ligand/Fas system in the brain: Regulator of immune and apoptotic responses

Brain Research Reviews

Volumn 44, Issue 1, 2004, Pages 65-81

  Choi, Chulhee ^a,b   Benveniste, Etty N ^b  

^a Ewha Womans University   (South Korea)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoptosis; Fas; Fas ligand; Immune Suppression; Inflammation

Indexed keywords

APOLIPOPROTEIN; APOPTOSIS SIGNAL REGULATING KINASE 1; CASPASE; CASPASE 8; CD134 ANTIGEN; CD70 ANTIGEN; CHEMOKINE; CYSTEINE; CYTOCHROME; CYTOKINE; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR; FAS ANTIGEN; FAS LIGAND; FRACTALKINE; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; LYMPHOTOXIN; MEMBRANE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

ALZHEIMER DISEASE; APOPTOSIS; ASTROCYTE; ASTROCYTOMA; B LYMPHOCYTE; BACTERIAL MENINGITIS; BRAIN; BRAIN CANCER; BRAIN DEGENERATION; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN MATURATION; CANCER CELL; CELL DEATH; CELL GROWTH; CELL KILLING; CELL PROLIFERATION; CELL REGENERATION; CENTRAL NERVOUS SYSTEM; CYTOTOXICITY; DOWN SYNDROME; ENDOTHELIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; HOST; HUMAN; HUNTINGTON CHOREA; HYDROCEPHALUS; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INFLAMMATION; MICROGLIA; MITOCHONDRION; MUTATION; NATURAL KILLER CELL; NERVE CELL; NEUROBLASTOMA; NEUROLOGIC DISEASE; NIEMANN PICK DISEASE; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; REMISSION; REVIEW; SHY DRAGER SYNDROME; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; STIMULATION; T LYMPHOCYTE;

EID: 1642575170     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2003.08.007     Document Type: Review

References (278)

1. Abreu-Martin M.T., Vidrich A., Lynch D.H., Targan S.R. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α and ligation of Fas antigen. J. Immunol. 155:1995;4147-4154.
2. Abreu-Martin M.T., Palladino A.A., Faris M., Carramanzana N.M., Nel A.E., Targan S.R. Fas activates the JNK pathway in human colonic epithelial cells: lack of a direct role in apoptosis. Am. J. Physiol. 276:1999;G599-G605.
3. Adachi M., Watanabe-Fukunaga R., Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc. Natl. Acad. Sci. U. S. A. 90:1993;1756-1760.
4. Adrain C., Creagh E.M., Martin S.J. Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J. 20:2001;6627-6636.
5. Aggarwal B.B., Singh S., LaPushin R., Totpal K. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett. 364:1995;5-8.
6. Ahn J.H., Park S.M., Cho H.S., Lee M.S., Yoon J.B., Vilcek J., Lee T.H. Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-κB-dependent gene expression. J. Biol. Chem. 276:2001;47100-47106.
7. Alderson M.R., Tough T.W., Braddy S., Davis-Smith T., Roux E., Schooley K., Miller R.E., Lynch D.H. Regulation of apoptosis and T cell activation by Fas-specific mAb. Int. Immunol. 6:1994;1799-1806.
8. Algeciras-Schimnich A., Shen L., Barnhart B.C., Murmann A.E., Burkhardt J.K., Peter M.E. Molecular ordering of the initial signaling events of CD95. Mol. Cell. Biol. 22:2002;207-220.
9. Allison J., Georgiou H.M., Strasser A., Vaux D.L. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3943-3947.
10. Ashkenazi A., Dixit V.M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11:1999;255-260.
11. Ayroldi E., Zollo O., Cannarile L., D'Adamio F., Grohmann U., Delfino D.V., Riccardi C. Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/FasL expression and cell death. Blood. 92:1998;4212-4219.
12. Ayroldi E., D'Adamio F., Zollo O., Agostini M., Moraca R., Cannarile L., Migliorati G., Delfino D.V., Riccardi C. Cloning and expression of a short Fas ligand: a new alternatively spliced product of the mouse Fas ligand gene. Blood. 94:1999;3456-3467.
13. Badie B., Schartner J., Vorpahl J., Preston K. Interferon-γ induces apoptosis and augments the expression of Fas and Fas ligand by microglia in vitro. Exp. Neurol. 162:2000;290-296.
14. Badie B., Schartner J., Prabakaran S., Paul J., Vorpahl J. Expression of Fas ligand by microglia: possible role in glioma immune evasion. J. Neuroimmunol. 120:2001;19-24.
15. Badorff C., Ruetten H., Mueller S., Stahmer M., Gehring D., Jung F., Ihling C., Zeiher A.M., Dimmeler S. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J. Clin. Invest. 109:2002;373-381.
16. Baud V., Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11:2001;372-377.
17. Becher B., Barker P.A., Owens T., Antel J.P. CD95-CD95L: can the brain learn from the immune system? Trends Neurosci. 21:1998;114-117.
18. Becher B., D'Souza S.D., Troutt A.B., Antel J.P. Fas expression on human fetal astrocytes without susceptibility to fas-mediated cytotoxicity. Neuroscience. 84:1998;627-634.
19. Bechmann I., Mor G., Nilsen J., Eliza M., Nitsch R., Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia. 27:1999;62-74.
20. Bechmann I., Lossau S., Steiner B., Mor G., Gimsa U., Nitsch R. Reactive astrocytes upregulate Fas (CD95) and Fas ligand (CD95L) expression but do not undergo programmed cell death during the course of anterograde degeneration. Glia. 32:2000;25-41.
21. Becker K., Schneider P., Hofmann K., Mattmann C., Tschopp J. Interaction of Fas(Apo-1/CD95) with proteins implicated in the ubiquitination pathway. FEBS Lett. 412:1997;102-106.
22. Beer R., Franz G., Schopf M., Reindl M., Zelger B., Schmutzhard E., Poewe W., Kampfl A. Expression of Fas and Fas ligand after experimental traumatic brain injury in the rat. J. Cereb. Blood Flow Metab. 20:2000;669-677.
23. Bennett M.W., O'Connell J., O'Sullivan G.C., Brady C., Roche D., Collins J.K., Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160:1998;5669-5675.
24. Beyaert R., Van L.G., Heyninck K., Vandenabeele P. Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas. Int. Rev. Cytol. 214:2002;225-272.
25. Boatright K.M., Renatus M., Scott F.L., Sperandio S., Shin H., Pedersen I.M., Ricci J.E., Edris W.A., Sutherlin D.P., Green D.R., Salvesen G.S. A unified model for apical caspase activation. Mol. Cell. 11:2003;529-541.
26. Bodey B., Bodey B. Jr., Siegel S.E., Kaiser H.E. Fas (APO-1, CD95) receptor expression and new options for immunotherapy in childhood medulloblastomas. Anticancer Res. 19:1999;3293-3314.
27. Bodey B., Bodey B. Jr., Siegel S.E., Kaiser H.E. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells? In Vivo. 13:1999;357-373.
28. Boehme S.A., Lio F.M., Maciejewski-Lenoir D., Bacon K.B., Conlon P.J. The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J. Immunol. 165:2000;397-403.
29. Bonetti B., Pohl J., Gao Y.L., Raine C.S. Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. J. Immunol. 159:1997;5733-5741.
30. Bonetti B., Raine C.S. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann. Neurol. 42:1997;74-84.
31. Boylan M.T., Crockard A.D., McDonnell G.V., McMillan S.A., Hawkins S.A. Serum and cerebrospinal fluid soluble Fas levels in clinical subgroups of multiple sclerosis. Immunol. Lett. 78:2001;183-187.
32. Carson M.J., Sutcliffe J.G. Balancing function vs. self defense: the CNS as an active regulator of immune responses. J. Neurosci. Res. 55:1999;1-8.
33. Cascino I., Fiucci G., Papoff G., Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154:1995;2706-2713.
34. Cascino I., Papoff G., De Maria R., Testi R., Ruberti G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 156:1996;13-17.
35. Cascino I.I., Papoff G., Eramo A., Ruberti G. Soluble Fas/Apo-1 splicing variants and apoptosis. Front. Biosci. 1:1996;d12-d18.
36. Casha S., Yu W.R., Fehlings M.G. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience. 103:2001;203-218.
37. Cefai D., Favre L., Wattendorf E., Marti A., Jaggi R., Gimmi C.D. Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model. Int. J. Cancer. 91:2001;529-537.
38. Chang H.Y., Nishitoh H., Yang X., Ichijo H., Baltimore D. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science. 281:1998;1860-1863.
39. Chang H.Y., Yang X., Baltimore D. Dissecting Fas signaling with an altered-specificity death-domain mutant: requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation. Proc. Natl. Acad. Sci. U. S. A. 96:1999;1252-1256.
40. Charette S.J., Lambert H., Landry J. A kinase-independent function of Ask1 in caspase-independent cell death. J. Biol. Chem. 276:2001;36071-36074.
41. Chaudhary P.M., Eby M.T., Jasmin A., Kumar A., Liu L., Hood L. Activation of the NF-κB pathway by caspase 8 and its homologs. Oncogene. 19:2000;4451-4460.
42. Chauhan D., Kharbanda S., Ogata A., Urashima M., Teoh G., Robertson M., Kufe D.W., Anderson K.C. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 89:1997;227-234.
43. Cheema Z.F., Wade S.B., Sata M., Walsh K., Sohrabji F., Miranda R.C. Fas/Apo [apoptosis]-1 and associated proteins in the differentiating cerebral cortex: induction of caspase-dependent cell death and activation of NF-κB. J. Neurosci. 19:1999;1754-1770.
44. Cheema Z.F., West J.R., Miranda R.C. Ethanol induces Fas/Apo [apoptosis]-1 mRNA and cell suicide in the developing cerebral cortex. Alcohol Clin. Exp. Res. 24:2000;535-543.
45. Chen J.J., Sun Y., Nabel G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 282:1998;1714-1717.
46. Chervonsky A.V., Wang Y., Wong F.S., Visintin I., Flavell R.A., Janeway C.A. Jr., Matis L.A. The role of Fas in autoimmune diabetes. Cell. 89:1997;17-24.
47. Choe W., Stoica G., Lynn W., Wong P.K. Neurodegeneration induced by MoMuLV-ts1 and increased expression of Fas and TNF-α in the central nervous system. Brain Res. 779:1998;1-8.
48. Choi C., Park J.Y., Lee J., Lim J.H., Shin E.C., Ahn Y.S., Kim C.H., Kim S.J., Kim J.D., Choi I.S., Choi I.H. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-α, or IFN-γ J. Immunol. 162:1999;1889-1895.
49. Choi C., Xu X., Oh J.W., Lee S.J., Gillespie G.Y., Park H., Jo H., Benveniste E.N. Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Cancer Res. 61:2001;3084-3091.
50. Choi Y.-H., Kim K.-B., Kim H.-H., Hong G.-S., Kwon Y.-K., Chung C.-W., Park Y.-M., Shen Z.-J., Kim B.J., Lee S.-Y., Jung Y.-K. FLASH Coordinates NF-κB Activity via TRAF2. J. Biol. Chem. 276:2001;25073-25077.
51. Choi C., Gillespie G.Y., Van Wagoner N.J., Benveniste E.N. Fas engagement increases expression of interleukin-6 in human glioma cells. J. Neurooncol. 56:2002;13-19.
52. Choi C., Kutsch O., Park J., Zhou T., Seol D.-W., Benveniste E.N. Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol. Cell. Biol. 22:2002;724-736.
53. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A., Blay J.Y. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today. 18:1997;493-497.
54. Chu K., Niu X., Williams L.T. A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;11894-11898.
55. Ciesielski-Treska J., Ulrich G., Chasserot-Golaz S., Zwiller J., Revel M.O., Aunis D., Bader M.F. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. J. Biol. Chem. 276:2001;13113-13120.
56. Cifone M.G., Roncaioli P., De Maria R., Camarda G., Santoni A., Ruberti G., Testi R. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J. 14:1995;5859-5868.
57. Ciusani E., Frigerio S., Gelati M., Corsini E., Dufour A., Nespolo A., La Mantia L., Milanese C., Massa G., Salmaggi A. Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 82:1998;5-12.
58. Ciusani E., Gelati M., Frigerio S., Pollo B., Massa G., Sacerdote P., Panerai A.E., Salmaggi A. Modulation of experimental allergic encephalomyelitis in Lewis rats by administration of a Peptide of fas ligand. J. Autoimmun. 17:2001;273-280.
59. Connolly K., Cho Y.H., Duan R., Fikes J., Gregorio T., LaFleur D.W., Okoye Z., Salcedo T.W., Santiago G., Ullrich S., Wei P., Windle K., Wong E., Yao X.T., Zhang Y.Q., Zheng G., Moore P.A. In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. J. Pharmacol. Exp. Ther. 298:2001;25-33.
60. Coulter K.R., Doseff A., Sweeney P., Wang Y., Marsh C.B., Wewers M.D., Knoell D.L. Opposing effect by cytokines on Fas-mediated apoptosis in A549 lung epithelial cells. Am. J. Respir. Cell. Mol. Biol. 26:2002;58-66.
61. Cremesti A., Paris F., Grassme H., Holler N., Tschopp J., Fuks Z., Gulbins E., Kolesnick R. Ceramide enables fas to cap and kill. J. Biol. Chem. 276:2001;23954-23961.
62. de la Monte S.M., Sohn Y.K., Wands J.R. Correlates of p53-and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J. Neurol. Sci. 152:1997;73-83.
63. de la Monte S.M., Sohn Y.K., Ganju N., Wands J.R. P53- and CD95-associated apoptosis in neurodegenerative diseases. Lab. Invest. 78:1998;401-411.
64. De Maria R., Rippo M.R., Schuchman E.H., Testi R. Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J. Exp. Med. 187:1998;897-902.
65. De Maria R., Testi R. Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Immunol. Today. 19:1998;121-125.
66. Deveraux Q.L., Schendel S.L., Reed J.C. Antiapoptotic proteins. The bcl-2 and inhibitor of apoptosis protein families. Cardiol. Clin. 19:2001;57-74.
67. Didenko V.V., Ngo H.N., Minchew C., Baskin D.S. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J. Neurosurg. 96:2002;580-584.
68. Dietrich P.Y., Walker P.R., Saas P. Death receptors on reactive astrocytes: a key role in the fine tuning of brain inflammation? Neurology. 60:2003;548-554.
69. Dittel B.N., Merchant R.M., Janeway C.A. Jr. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 162:1999;6392-6400.
70. Dowling P., Shang G., Raval S., Menonna J., Cook S., Husar W. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 184:1996;1513-1518.
71. D'Souza S.D., Bonetti B., Balasingam V., Cashman N.R., Barker P.A., Troutt A.B., Raine C.S., Antel J.P. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med. 184:1996;2361-2370.
72. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 68:1999;383-424.
73. Ehrmann J. Jr., Rihakova P., Hlobilkova A., Kala M., Kolar Z. The expression of apoptosis-related proteins and the apoptotic rate in glial tumors of the brain. Neoplasma. 47:2000;151-155.
74. Elovaara I., Sabri F., Gray F., Alafuzoff I., Chiodi F. Upregulated expression of Fas and Fas ligand in brain through the spectrum of HIV-1 infection. Acta Neuropathol. (Berl.). 98:1999;355-362.
75. Ertel W., Keel M., Stocker R., Imhof H.G., Leist M., Steckholzer U., Tanaka M., Trentz O., Nagata S. Detectable concentrations of Fas ligand in cerebrospinal fluid after severe head injury. J. Neuroimmunol. 80:1997;93-96.
76. Eves E.M., Skoczylas C., Yoshida K., Alnemri E.S., Rosner M.R. FGF induces a switch in death receptor pathways in neuronal cells. J. Neurosci. 21:2001;4996-5006.
77. Fadeel B., Thorpe J., Chiodi F. Mapping of the linear site on the Fas/APO-1 molecule targeted by the prototypic anti-Fas mAb. Int. Immunol. 7:1995;1967-1975.
78. Farbman A.I., Buchholz J.A., Suzuki Y., Coines A., Speert D. A molecular basis of cell death in olfactory epithelium. J. Comp. Neurol. 414:1999;306-314.
79. Fassbender K., Eschenfelder C., Hennerici M. Fas (APO-1/CD95) in inflammatory CNS diseases: intrathecal release in bacterial meningitis. J. Neuroimmunol. 93:1999;122-125.
80. Felderhoff-Mueser U., Herold R., Hochhaus F., Koehne P., Ring-Mrozik E., Obladen M., Buhrer C. Increased cerebrospinal fluid concentrations of soluble Fas (CD95/Apo-1) in hydrocephalus. Arch. Dis. Child. 84:2001;369-372.
81. Ferrer I., Blanco R., Cutillas B., Ambrosio S. Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Neuropathol. Appl. Neurobiol. 26:2000;424-433.
82. Ferrer I., Puig B., Krupinsk J., Carmona M., Blanco R. Fas and Fas ligand expression in Alzheimer's disease. Acta Neuropathol. (Berl.). 102:2001;121-131.
83. Flugel A., Bradl M. New tools to trace populations of inflammatory cells in the CNS. Glia. 36:2001;125-136.
84. Flugel A., Schwaiger F.W., Neumann H., Medana I., Willem M., Wekerle H., Kreutzberg G.W., Graeber M.B. Neuronal FasL induces cell death of encephalitogenic T lymphocytes. Brain Pathol. 10:2000;353-364.
85. Flugel A., Berkowicz T., Ritter T., Labeur M., Jenne D.E., Li Z., Ellwart J.W., Willem M., Lassmann H., Wekerle H. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity. 14:2001;547-560.
86. Flugel A., Bradl M., Kreutzberg G.W., Graeber M.B. Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J. Neurosci. Res. 66:2001;74-82.
87. Frankel B., Longo S.L., Ryken T.C. Co-expression of Fas and Fas ligand in human non-astrocytic glial tumors. Acta Neuropathol. (Berl.). 98:1999;363-366.
88. Frankel B., Longo S.L., Ryken T.C. Human astrocytomas co-expressing Fas and Fas ligand also produce TGFb2 and Bcl-2. J. Neurooncol. 44:1999;205-212.
89. Frankel B., Longo S.L., Canute G.W. Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion. J. Neurooncol. 48:2000;21-26.
90. Frei K., Ambar B., Adachi N., Yonekawa Y., Fontana A. Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis. J. Neuroimmunol. 87:1998;105-113.
91. French L.E., Tschopp J. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover. Behring-Inst.-Mitt. 1996;156-160.
92. Frigerio S., Silei V., Ciusani E., Massa G., Lauro G.M., Salmaggi A. Modulation of fas-ligand (Fas-L) on human microglial cells: an in vitro study. J. Neuroimmunol. 105:2000;109-114.
93. Gibson S., Tu S., Oyer R., Anderson S.M., Johnson G.L. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J. Biol. Chem. 274:1999;17612-17618.
94. Gloor S.M., Wachtel M., Bolliger M.F., Ishihara H., Landmann R., Frei K. Molecular and cellular permeability control at the blood-brain barrier. Brain Res. Brain Res. Rev. 36:2001;258-264.
95. Golstein P. Signal transduction: FasL binds preassembled Fas. Science. 288:2000;2328-2329.
96. Grassme H., Jekle A., Riehle A., Schwarz H., Berger J., Sandhoff K., Kolesnick R., Gulbins E. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276:2001;20589-20596.
97. Gratas C., Tohma Y., Van Meir E.G., Klein M., Tenan M., Ishii N., Tachibana O., Kleihues P., Ohgaki H. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7:1997;863-869.
98. Green D.R., Ferguson T.A. The role of Fas ligand in immune privilege. Nat. Rev. Mol. Cell. Biol. 2:2001;917-924.
99. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
100. Grimm S., Stanger B.Z., Leder P. RIP and FADD: two "death domain"-containing proteins can induce apoptosis by convergent, but dissociable, pathways. Proc. Natl. Acad. Sci. U. S. A. 93:1996;10923-10927.
101. Grullich C., Sullards M.C., Fuks Z., Merrill A.H. Jr., Kolesnick R. CD95(Fas/APO-1) signals ceramide generation independent of the effector stage of apoptosis. J. Biol. Chem. 275:2000;8650-8656.
102. Gulbins E., Bissonnette R., Mahboubi A., Martin S., Nishioka W., Brunner T., Baier G., Baier-Bitterlich G., Byrd C., Lang F.et al. FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity. 2:1995;341-351.
103. Gulbins E., Coggeshall K.M., Brenner B., Schlottmann K., Linderkamp O., Lang F. Fas-induced apoptosis is mediated by activation of a Ras and Rac protein-regulated signaling pathway. J. Biol. Chem. 271:1996;26389-26394.
104. Gulbins E., Brenner B., Koppenhoefer U., Linderkamp O., Lang F. Fas or ceramide induce apoptosis by Ras-regulated phosphoinositide-3-kinase activation. J. Leukoc. Biol. 63:1998;253-263.
105. Hagimoto N., Kuwano K., Kawasaki M., Yoshimi M., Kaneko Y., Kunitake R., Maeyama T., Tanaka T., Hara N. Induction of interleukin-8 secretion and apoptosis in bronchiolar epithelial cells by Fas ligation. Am. J. Respir. Cell. Mol. Biol. 21:1999;436-445.
106. Hishii M., Kurnick J.T., Ramirez-Montagut T., Pandolfi F. Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes. Clin. Exp. Immunol. 116:1999;388-394.
107. Hohlbaum A.M., Gregory M.S., Ju S.T., Marshak-Rothstein A. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J. Immunol. 167:2001;6217-6224.
108. Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., Bodmer J.L., Schneider P., Seed B., Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1:2000;489-495.
109. Holler N., Tardivel A., Kovacsovics-Bankowski M., Hertig S., Gaide O., Martinon F., Tinel A., Deperthes D., Calderara S., Schulthess T., Engel J., Schneider P., Tschopp J. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 23:2003;1428-1440.
110. Holmstrom T.H., Chow S.C., Elo I., Coffey E.T., Orrenius S., Sistonen L., Eriksson J.E. Suppression of Fas/APO-1-mediated apoptosis by mitogen-activated kinase signaling. J. Immunol. 160:1998;2626-2636.
111. Holmstrom T.H., Tran S.E., Johnson V.L., Ahn N.G., Chow S.C., Eriksson J.E. Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol. Cell. Biol. 19:1999;5991-6002.
112. Holmstrom T.H., Schmitz I., Soderstrom T.S., Poukkula M., Johnson V.L., Chow S.C., Krammer P.H., Eriksson J.E. MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. EMBO J. 19:2000;5418-5428.
113. Honig L.S., Rosenberg R.N. Apoptosis and neurologic disease. Am. J. Med. 108:2000;317-330.
114. Hornig M., Weissenbock H., Horscroft N., Lipkin W.I. An infection-based model of neurodevelopmental damage. Proc. Natl. Acad. Sci. U. S. A. 96:1999;12102-12107.
115. Hu W.H., Johnson H., Shu H.B. Activation of NF-κB by FADD, Casper, and caspase-8. J. Biol. Chem. 275:2000;10838-10844.
116. Huang D., Han Y., Rani M.R., Glabinski A., Trebst C., Sorensen T., Tani M., Wang J., Chien P., O'Bryan S., Bielecki B., Zhou Z.L., Majumder S., Ransohoff R.M. Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol. Rev. 177:2000;52-67.
117. Husain N., Chiocca E.A., Rainov N., Louis D.N., Zervas N.T. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol. (Berl.). 95:1998;287-290.
118. Ichinose M., Masuoka J., Shiraishi T., Mineta T., Tabuchi K. Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors. Brain Tumor Pathol. 18:2001;37-42.
119. Idriss H.T., Naismith J.H. TNF-α and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech. 50:2000;184-195.
120. Ilzecka J., Stelmasiak Z., Dobosz B. Interleukin-1β converting enzyme/Caspase-1 (ICE/Caspase-1) and soluble APO-1/Fas/CD 95 receptor in amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 103:2001;255-258.
121. Imai Y., Kimura T., Murakami A., Yajima N., Sakamaki K., Yonehara S. The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis. Nature. 398:1999;777-785.
122. Inoue A., Koh C.S., Sakai T., Yamazaki M., Yanagisawa N., Usuku K., Osame M. Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J. Neuroimmunol. 75:1997;141-146.
123. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195.
124. Itoh N., Imagawa A., Hanafusa T., Waguri M., Yamamoto K., Iwahashi H., Moriwaki M., Nakajima H., Miyagawa J., Namba M., Makino S., Nagata S., Kono N., Matsuzawa Y. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186:1997;613-618.
125. Izikson L., Klein R.S., Charo I.F., Weiner H.L., Luster A.D. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192:2000;1075-1080.
126. Jamieson E., Jeffrey M., Ironside J.W., Fraser J.R. Activation of Fas and caspase 3 precedes PrP accumulation in 87V scrapie. NeuroReport. 12:2001;3567-3572.
127. Jenkins M., Keir M., McCune J.M. A membrane-bound Fas decoy receptor expressed by human thymocytes. J. Biol. Chem. 275:2000;7988-7993.
128. Jin K., Graham S.H., Mao X., Nagayama T., Simon R.P., Greenberg D.A. Fas (CD95) may mediate delayed cell death in hippocampal CA1 sector after global cerebral ischemia. J. Cereb. Blood Flow Metab. 21:2001;1411-1421.
129. Kamada H., Murakami H., Satone A., Ikeda M., Yamaguchi H., Matsumoto A., Ide W., Hashimoto I., Ukita H. Up-regulation of NGF, trkA, Fas, down-regulation of bcl-2, and induction of apoptosis by propentofylline in human glioma cell lines. No To Shinkei. 48:1996;1022-1028.
130. Kang S.M., Schneider D.B., Lin Z., Hanahan D., Dichek D.A., Stock P.G., Baekkeskov S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:1997;738-743.
131. Kataoka T., Budd R.C., Holler N., Thome M., Martinon F., Irmler M., Burns K., Hahne M., Kennedy N., Kovacsovics M., Tschopp J. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr. Biol. 10:2000;640-648.
132. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1995;1777-1783.
133. Kelliher M.A., Grimm S., Ishida Y., Kuo F., Stanger B.Z., Leder P. The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity. 8:1998;297-303.
134. Kennedy N.J., Budd R.C. Phosphorylation of FADD/MORT1 and Fas by kinases that associate with the membrane-proximal cytoplasmic domain of Fas. J. Immunol. 160:1998;4881-4888.
135. Kim S., Kim K.A., Hwang D.Y., Lee T.H., Kayagaki N., Yagita H., Lee M.S. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved. J. Immunol. 164:2000;2931-2936.
136. Kohji T., Matsumoto Y. Coexpression of Fas/FasL and Bax on brain and infiltrating T cells in the central nervous system is closely associated with apoptotic cell death during autoimmune encephalomyelitis. J. Neuroimmunol. 106:2000;165-171.
137. Kolasa K., Harrell L.E. Apoptotic protein expression and activation of caspases is changed following cholinergic denervation and hippocampal sympathetic ingrowth in rat hippocampus. Neuroscience. 101:2000;541-546.
138. Koonin E.V., Aravind L., Hofmann K., Tschopp J., Dixit V.M. Apoptosis. Searching for FLASH domains. Nature. 401(662):1999;662-663. (discussion).
139. Kovalovich K., Li W., DeAngelis R., Greenbaum L.E., Ciliberto G., Taub R. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J. Biol. Chem. 276:2001;26605-26613.
140. Lee R.K., Spielman J., Zhao D.Y., Olsen K.J., Podack E.R. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J. Immunol. 157:1996;1919-1925.
141. Lee S.J., Zhou T., Choi C., Wang Z., Benveniste E.N. Differential regulation and function of Fas expression on glial cells. J. Immunol. 164:2000;1277-1285.
142. Le-Niculescu H., Bonfoco E., Kasuya Y., Claret F.X., Green D.R., Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell. Biol. 19:1999;751-763.
143. Lenzlinger P.M., Marx A., Trentz O., Kossmann T., Morganti-Kossmann M.C. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans. J. Neuroimmunol. 122:2002;167-174.
144. Li H., Yuan J. Deciphering the pathways of life and death. Curr. Opin. Cell Biol. 11:1999;261-266.
145. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:1998;491-501.
146. Li G.L., Farooque M., Olsson Y. Changes of Fas and Fas ligand immunoreactivity after compression trauma to rat spinal cord. Acta Neuropathol. (Berl.). 100:2000;75-81.
147. Lin T., Genestier L., Pinkoski M.J., Castro A., Nicholas S., Mogil R., Paris F., Fuks Z., Schuchman E.H., Kolesnick R.N., Green D.R. Role of acidic sphingomyelinase in Fas/CD95-mediated cell death. J. Biol. Chem. 275:2000;8657-8663.
148. Lin Y., Devin A., Cook A., Keane M.M., Kelliher M., Lipkowitz S., Liu Z.G. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkB kinase and c-Jun N-terminal kinase. Mol. Cell. Biol. 20:2000;6638-6645.
149. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 104:2001;487-501.
150. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:1998;481-490.
151. Magnusson C., Vaux D.L. Signalling by CD95 and TNF receptors: not only life and death. Immunol. Cell Biol. 77:1999;41-46.
152. Malinin N.L., Boldin M.P., Kovalenko A.V., Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature. 385:1997;540-544.
153. Malipiero U., Frei K., Spanaus K.S., Agresti C., Lassmann H., Hahne M., Tschopp J., Eugster H.P., Fontana A. Myelin oligodendrocyte glycoprotein- induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice. Eur. J. Immunol. 27:1997;3151-3160.
154. Maric D., Millward J.M., Ballok D.A., Szechtman H., Denburg J.A., Barker J.L., Sakic B. Neurotoxic properties of cerebrospinal fluid from behaviorally impaired autoimmune mice. Brain Res. 920:2001;183-193.
155. Martin L.J. Neuronal cell death in nervous system development, disease, and injury. (Review) Int. J. Mol. Med. 7:2001;455-478.
156. Martin D.A., Zheng L., Siegel R.M., Huang B., Fisher G.H., Wang J., Jackson C.E., Puck J.M., Dale J., Straus S.E., Peter M.E., Krammer P.H., Fesik S., Lenardo M.J. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc. Natl. Acad. Sci. U. S. A. 96:1999;4552-4557.
157. Martinez M., Fernandez-Vivancos E., Frank A., De la Fuente M., Hernanz A. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations. Brain Res. 869:2000;216-219.
158. Martin-Villalba A., Herr I., Jeremias I., Hahne M., Brandt R., Vogel J., Schenkel J., Herdegen T., Debatin K.M. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19:1999;3809-3817.
159. Marx P.T., Mulder A.B., Van Den Bergh F.A., Overbeeke R., Haanen C., Vermes I. Apoptosis inducers endotoxin and Fas-ligation enhance the expression of vascular endothelial growth factor in human endothelial cells. Endothelium. 6:1999;335-340.
160. Matsumura H., Shimizu Y., Ohsawa Y., Kawahara A., Uchiyama Y., Nagata S. Necrotic death pathway in Fas receptor signaling. J. Cell Biol. 151:2000;1247-1256.
161. Matsuyama T., Hata R., Yamamoto Y., Tagaya M., Akita H., Uno H., Wanaka A., Furuyama J., Sugita M. Localization of Fas antigen mRNA induced in postischemic murine forebrain by in situ hybridization. Brain Res. Mol. Brain Res. 34:1995;166-172.
162. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell. Biol. 1:2000;120-129.
163. Medana I., Li Z., Flugel A., Tschopp J., Wekerle H., Neumann H. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity. J. Immunol. 167:2001;674-681.
164. Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., Hong J.S., Perry J.W., Chen S.F., Zhou J.X., Cho Y.H., Ullrich S., Kanakaraj P., Carrell J., Boyd E., Olsen H.S., Hu G., Pukac L., Liu D., Ni J., Kim S., Gentz R., Feng P., Moore P.A., Ruben S.M., Wei P. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 16:2002;479-492.
165. Mitsiades N., Yu W.H., Poulaki V., Tsokos M., Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61:2001;577-581.
166. Mogi M., Harada M., Kondo T., Mizuno Y., Narabayashi H., Riederer P., Nagatsu T. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci. Lett. 220:1996;195-198.
167. Muzio M., Stockwell B.R., Stennicke H.R., Salvesen G.S., Dixit V.M. An induced proximity model for caspase-8 activation. J. Biol. Chem. 273:1998;2926-2930.
168. Nagata S. Fas ligand-induced apoptosis. Annu. Rev. Genet. 33:1999;29-55.
169. Nagata S., Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol. Today. 16:1995;39-43.
170. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm. Suppl. 60:2000;277-290.
171. Neumann H. The immunological microenvironment in the CNS: implications on neuronal cell death and survival. J. Neural Transm. Suppl. 59:2000;59-68.
172. Nilsen J., Mor G., Naftolin F. Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J. Neurobiol. 43:2000;64-78.
173. Nishimura T., Akiyama H., Yonehara S., Kondo H., Ikeda K., Kato M., Iseki E., Kosaka K. Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res. 695:1995;137-145.
174. Northington F.J., Ferriero D.M., Flock D.L., Martin L.J. Delayed neurodegeneration in neonatal rat thalamus after hypoxia-ischemia is apoptosis. J. Neurosci. 21:2001;1931-1938.
175. O'Connell J., Bennett M.W., Nally K., O'Sullivan G.C., Collins J.K., Shanahan F. Interferon-γ sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis. J. Cell. Physiol. 185:2000;331-338.
176. O'Connell J., Houston A., Bennett M.W., O'Sullivan G.C., Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat. Med. 7:2001;271-274.
177. Okuda Y., Bernard C.C., Fujimura H., Yanagihara T., Sakoda S. Fas has a crucial role in the progression of experimental autoimmune encephalomyelitis. Mol. Immunol. 35:1998;317-326.
178. Okuda Y., Sakoda S., Fujimura H., Nagata S., Yanagihara T., Bernard C.C. Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 275:2000;164-168.
179. Okura T., Gong L., Kamitani T., Wada T., Okura I., Wei C.F., Chang H.M., Yeh E.T. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol. 157:1996;4277-4281.
180. Ottonello L., Tortolina G., Amelotti M., Dallegri F. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 162:1999;3601-3606.
181. Ouallet J., Baumann N., Marie Y., Villarroya H. Fas system up-regulation in experimental autoimmune encephalomyelitis. J. Neurol. Sci. 170:1999;96-104.
182. Palma J.P., Yauch R.L., Lang S., Kim B.S. Potential role of CD4+T cell-mediated apoptosis of activated astrocytes in Theiler's virus-induced demyelination. J. Immunol. 162:1999;6543-6551.
183. Park C., Sakamaki K., Tachibana O., Yamashima T., Yamashita J., Yonehara S. Expression of fas antigen in the normal mouse brain. Biochem. Biophys. Res. Commun. 252:1998;623-628.
184. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., Huang A., Donahue C.J., Sherwood S.W., Baldwin D.T., Godowski P.J., Wood W.I., Gurney A.L., Hillan K.J., Cohen R.L., Goddard A.D., Botstein D., Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 396:1998;699-703.
185. Platten M., Wick W., Weller M. Malignant glioma biology: role for TGF-β in growth, motility, angiogenesis, and immune escape. Microsc. Res. Tech. 52:2001;401-410.
186. Pouly S., Becher B., Blain M., Antel J.P. Interferon-γ modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J. Neuropathol. Exp. Neurol. 59:2000;280-286.
187. Prat A., Biernacki K., Wosik K., Antel J.P. Glial cell influence on the human blood-brain barrier. Glia. 36:2001;145-155.
188. Priller J., Flugel A., Wehner T., Boentert M., Haas C.A., Prinz M., Fernandez-Klett F., Prass K., Bechmann I., de Boer B.A., Frotscher M., Kreutzberg G.W., Persons D.A., Dirnagl U. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med. 7:2001;1356-1361.
189. Puig B., Ferrer I. Cell death signaling in the cerebellum in Creutzfeldt-Jakob disease. Acta Neuropathol. (Berl.). 102:2001;207-215.
190. Raine C.S., Bonetti B., Cannella B. Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque. Rev. Neurol. (Paris). 154:1998;577-585.
191. Raoul C., Henderson C.E., Pettmann B. Programmed cell death of embryonic motoneurons triggered through the Fas death receptor. J. Cell Biol. 147:1999;1049-1062.
192. Ravagnan L., Roumier T., Kroemer G. Mitochondria, the killer organelles and their weapons. J. Cell. Physiol. 192:2002;131-137.
193. Rensing-Ehl A., Hess S., Ziegler-Heitbrock H.W., Riethmuller G., Engelmann H. Fas/Apo-1 activates nuclear factor κB and induces interleukin-6 production. J. Inflamm. 45:1995;161-174.
194. Riffkin C.D., Gray A.Z., Hawkins C.J., Chow C.W., Ashley D.M. Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. Neuro-oncology. 3:2001;229-240.
195. 2-terminal kinase activation. J. Exp. Med. 192:2000;1165-1174.
196. Roebuck K.A. Regulation of interleukin-8 gene expression. J. Interferon Cytokine Res. 19:1999;429-438.
197. Rosenbaum D.M., Gupta G., D'Amore J., Singh M., Weidenheim K., Zhang H., Kessler J.A. Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemia. J. Neurosci. Res. 61:2000;686-692.
198. Roths J.B., Murphy E.D., Eicher E.M. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J. Exp. Med. 159:1984;1-20.
199. Ruiz-Ruiz C., Munoz-Pinedo C., Lopez-Rivas A. Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res. 60:2000;5673-5680.
200. Saas P., Walker P.R., Hahne M., Quiquerez A.L., Schnuriger V., Perrin G., French L., Van Meir E.G., de Tribolet N., Tschopp J., Dietrich P.Y. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99:1997;1173-1178.
201. Saas P., Boucraut J., Quiquerez A.L., Schnuriger V., Perrin G., Desplat-Jego S., Bernard D., Walker P.R., Dietrich P.Y. CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation? J. Immunol. 162:1999;2326-2333.
202. Sabelko K.A., Kelly K.A., Nahm M.H., Cross A.H., Russell J.H. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159:1997;3096-3099.
203. Sabelko-Downes K.A., Cross A.H., Russell J.H. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J. Exp. Med. 189:1999;1195-1205.
204. Sabelko-Downes K.A., Russell J.H., Cross A.H. Role of Fas-FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease. J. Neuroimmunol. 100:1999;42-52.
205. Sabri F., De Milito A., Pirskanen R., Elovaara I., Hagberg L., Cinque P., Price R., Chiodi F. Elevated levels of soluble Fas and Fas ligand in cerebrospinal fluid of patients with AIDS dementia complex. J. Neuroimmunol. 114:2001;197-206.
206. Saito M., Nakamura N., Nagai M., Shirakawa K., Sato H., Kawahigashi N., Furukawa Y., Usuku K., Nakagawa M., Izumo S., Osame M. Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients. J. Neuroimmunol. 98:1999;221-226.
207. Sata M., Suhara T., Walsh K. Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy. Arterioscler. Thromb. Vasc. Biol. 20:2000;309-316.
208. Sato T., Irie S., Kitada S., Reed J.C. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science. 268:1995;411-415.
209. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1998;1675-1687.
210. Scaffidi C., Schmitz I., Krammer P.H., Peter M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 274:1999;1541-1548.
211. Schaub F.J., Han D.K., Liles W.C., Adams L.D., Coats S.A., Ramachandran R.K., Seifert R.A., Schwartz S.M., Bowen-Pope D.F. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat. Med. 6:2000;790-796.
212. Schlapbach R., Spanaus K.S., Malipiero U., Lens S., Tasinato A., Tschopp J., Fontana A. TGF-β induces the expression of the FLICE-inhibitory protein and inhibits Fas-mediated apoptosis of microglia. Eur. J. Immunol. 30:2000;3680-3688.
213. Schlottmann K.E., Gulbins E., Lau S.M., Coggeshall K.M. Activation of Src-family tyrosine kinases during Fas-induced apoptosis. J. Leukoc. Biol. 60:1996;546-554.
214. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1998;1205-1213.
215. Schneider T.J., Fischer G.M., Donohoe T.J., Colarusso T.P., Rothstein T.L. A novel gene coding for a Fas apoptosis inhibitory molecule (FAIM) isolated from inducibly Fas-resistant B lymphocytes. J. Exp. Med. 189:1999;949-956.
216. Schwandner R., Wiegmann K., Bernardo K., Kreder D., Kronke M. TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase. J. Biol. Chem. 273:1998;5916-5922.
217. Seidl R., Fang-Kircher S., Bidmon B., Cairns N., Lubec G. Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brains of adult patients with Down syndrome. Neurosci. Lett. 260:1999;9-12.
218. Seino K., Iwabuchi K., Kayagaki N., Miyata R., Nagaoka I., Matsuzawa A., Fukao K., Yagita H., Okumura K. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161:1998;4484-4488.
219. Sekine C., Yagita H., Kobata T., Hasunuma T., Nishioka K., Okumura K. Fas-mediated stimulation induces IL-8 secretion by rheumatoid arthritis synoviocytes independently of CPP32-mediated apoptosis. Biochem. Biophys. Res. Commun. 228:1996;14-20.
220. Shimada M., Andoh A., Araki Y., Fujiyama Y., Bamba T. Ligation of the Fas antigen stimulates chemokine secretion in pancreatic cancer cell line PANC-1. J. Gastroenterol. Hepatol. 16:2001;1060-1067.
221. Shin S.W., Park J.W., Suh M.H., Suh S.I., Choe B.K. Persistent expression of Fas/FasL mRNA in the mouse hippocampus after a single NMDA injection. J. Neurochem. 71:1998;1773-1776.
222. Shin D.H., Lee E., Kim H.J., Kim S., Cho S.S., Chang K.Y., Lee W.J. Fas ligand mRNA expression in the mouse central nervous system. J. Neuroimmunol. 123:2002;50-57.
223. Shinohara H., Yagita H., Ikawa Y., Oyaizu N. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res. 60:2000;1766-1772.
224. Siegel R.M., Frederiksen J.K., Zacharias D.A., Chan F.K., Johnson M., Lynch D., Tsien R.Y., Lenardo M.J. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 288:2000;2354-2357.
225. Spanaus K.S., Schlapbach R., Fontana A. TNF-α and IFN-γ render microglia sensitive to Fas ligand-induced apoptosis by induction of Fas expression and down-regulation of Bcl-2 and Bcl-XL. Eur. J. Immunol. 28:1998;4398-4408.
226. Sporer B., Koedel U., Goebel F.D., Pfister H.W. Increased levels of soluble Fas receptor and Fas ligand in the cerebrospinal fluid of HIV-infected patients. AIDS Res. Hum. Retrovir. 16:2000;221-226.
227. Stanger B.Z., Leder P., Lee T.H., Kim E., Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 81:1995;513-523.
228. Steinbach J.P., Supra P., Huang H.J., Cavenee W.K., Weller M. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathol. 12:2002;12-20.
229. Streffer J.R., Schuster M., Zipp F., Weller M. Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy? J. Neurooncol. 40:1998;233-235.
230. Suda T., Hashimoto H., Tanaka M., Ochi T., Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186:1997;2045-2050.
231. Suk K., Chang I., Kim Y.H., Kim S., Kim J.Y., Kim H., Lee M.S. Interferon-γ (IFN-γ) and tumor necrosis factor-α synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFN-γ inhibits cytoprotective NF-κB through STAT1/IRF-1 pathways. J. Biol. Chem. 276:2001;13153-13159.
232. Sun D., Whitaker J.N., Cao L., Han Q., Sun S., Coleclough C., Mountz J., Zhou T. Cell death mediated by Fas-FasL interaction between glial cells and MBP-reactive T cells. J. Neurosci. Res. 52:1998;458-467.
233. Suvannavejh G.C., Dal Canto M.C., Matis L.A., Miller S.D. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 105:2000;223-231.
234. Suzuki A., Hayashida M., Kawano H., Sugimoto K., Nakano T., Shiraki K. Hepatocyte growth factor promotes cell survival from Fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology. 32:2000;796-802.
235. Tachibana O., Nakazawa H., Lampe J., Watanabe K., Kleihues P., Ohgaki H. Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res. 55:1995;5528-5530.
236. Tachibana O., Lampe J., Kleihues P., Ohgaki H. Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol. (Berl.). 92:1996;431-434.
237. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:1994;969-976.
238. Takeuchi T., Ueki T., Nishimatsu H., Kajiwara T., Ishida T., Jishage K., Ueda O., Suzuki H., Li B., Moriyama N., Kitamura T. Accelerated rejection of Fas ligand-expressing heart grafts. J. Immunol. 162:1999;518-522.
239. Tan Z., Levid J., Schreiber S.S. Increased expression of Fas (CD95/APO-1) in adult rat brain after kainate-induced seizures. NeuroReport. 12:2001;1979-1982.
240. Tanaka M., Suda T., Takahashi T., Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 14:1995;1129-1135.
241. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat. Med. 4:1998;31-36.
242. Tarkowski E., Rosengren L., Blomstrand C., Jensen C., Ekholm S., Tarkowski A. Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke. 30:1999;321-327.
243. Taylor A.W. Neuroimmunomodulation in immune privilege: role of neuropeptides in ocular immunosuppression. Neuroimmunomodulation. 3:1996;195-204.
244. Timmer T., de Vries E.G., de Jong S. Fas receptor-mediated apoptosis: a clinical application? J. Pathol. 196:2002;125-134.
245. Tohma Y., Gratas C., Van Meir E.G., Desbaillets I., Tenan M., Tachibana O., Kleihues P., Ohgaki H. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J. Neuropathol. Exp. Neurol. 57:1998;239-245.
246. Toyoshima F., Moriguchi T., Nishida E. Fas induces cytoplasmic apoptotic responses and activation of the MKK7-JNK/SAPK and MKK6-p38 pathways independent of CPP32-like proteases. J. Cell Biol. 139:1997;1005-1015.
247. Tran S.E., Holmstrom T.H., Ahonen M., Kahari V.M., Eriksson J.E. MAPK/ ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276:2001;16484-16490.
248. Tuohy V.K., Yu M., Yin L., Kawczak J.A., Kinkel R.P. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 189:1999;1033-1042.
249. Turner C., Schapira A.H. Mitochondrial dysfunction in neurodegenerative disorders and ageing. Adv. Exp. Med. Biol. 487:2001;229-251.
250. Umehara F., Itoh K., Michizono K., Abe M., Izumo S., Osame M. Involvement of Fas/Fas ligand system in the spinal cords of HTLV-I-associated myelopathy. Acta Neuropathol. (Berl.). 103:2002;384-390.
251. Van Wagoner N.J., Benveniste E.N. Interleukin-6 expression and regulation in astrocytes. J. Neuroimmunol. 100:1999;124-139.
252. Varela N., Munoz-Pinedo C., Ruiz-Ruiz C., Robledo G., Pedroso M., Lopez-Rivas A. Interferon-. sensitizes human myeloid leukemia cells to death receptor-mediated apoptosis by a pleiotropic mechanism. J. Biol. Chem. 276:2001;17779-17787.
253. Verhagen A.M., Vaux D.L. Cell death regulation by the mammalian IAP antagonist Diablo/Smac. Apoptosis. 7:2002;163-166.
254. Vogt M., Bauer M.K., Ferrari D., Schulze-Osthoff K. Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-1/Fas) ligand expression in microglial cells. FEBS Lett. 429:1998;67-72.
255. Waldner H., Sobel R.A., Howard E., Kuchroo V.K. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159:1997;3100-3103.
256. Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17:1999;331-367.
257. Walsh K., Sata M. Is extravasation a Fas-regulated process? Mol. Med. Today. 5:1999;61-67.
258. Walsh K., Sata M. Negative regulation of inflammation by Fas ligand expression on the vascular endothelium. Trends Cardiovasc. Med. 9:1999;34-41.
259. Wang X., DeFrances M.C., Dai Y., Pediaditakis P., Johnson C., Bell A., Michalopoulos G.K., Zarnegar R. A mechanism of cell survival. Sequestration of Fas by the HGF receptor Met. Mol. Cell. 9:2002;411-421.
260. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314-317.
261. Weber C.H., Vincenz C. The death domain superfamily: a tale of two interfaces? Trends Biochem. Sci. 26:2001;475-481.
262. Weller M., Frei K., Groscurth P., Krammer P.H., Yonekawa Y., Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94:1994;954-964.
263. White C.A., McCombe P.A., Pender M.P. Microglia are more susceptible than macrophages to apoptosis in the central nervous system in experimental autoimmune encephalomyelitis through a mechanism not involving Fas (CD95). Int. Immunol. 10:1998;935-941.
264. White C.A., McCombe P.A., Pender M.P. The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 82:1998;47-55.
265. White C.A., Nguyen K.B., Pender M.P. B cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis: roles of B cell CD95, CD95L and Bcl-2 expression. J. Autoimmun. 14:2000;195-204.
266. Wildbaum G., Westermann J., Maor G., Karin N. A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J. Clin. Invest. 106:2000;671-679.
267. Wisniewski S.A., Kobielak A., Trzeciak W.H., Kobielak K. Recent advances in understanding of the molecular basis of anhidrotic ectodermal dysplasia: discovery of a ligand, ectodysplasin A and its two receptors. J. Appl. Genet. 43:2002;97-107.
268. Wosik K., Becher B., Ezman A., Nalbantoglu J., Antel J.P. Caspase 8 expression and signaling in Fas injury-resistant human fetal astrocytes. Glia. 33:2001;217-224.
269. Wright D.A., Futcher B., Ghosh P., Geha R.S. Association of human fas (CD95) with a ubiquitin-conjugating enzyme (UBC-FAP). J. Biol. Chem. 271:1996;31037-31043.
270. Yang X., Khosravi-Far R., Chang H.Y., Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 89:1997;1067-1076.
271. Yeh W.C., Itie A., Elia A.J., Ng M., Shu H.B., Wakeham A., Mirtsos C., Suzuki N., Bonnard M., Goeddel D.V., Mak T.W. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity. 12:2000;633-642.
272. Yi F.H., Lautrette C., Vermot-Desroches C., Bordessoule D., Couratier P., Wijdenes J., Preud'homme J.L., Jauberteau M.O. In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients. J. Neuroimmunol. 109:2000;211-220.
273. Yu K.Y., Kwon B., Ni J., Zhai Y., Ebner R., Kwon B.S. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274:1999;13733-13736.
274. Zamai L., Ahmad M., Bennett I.M., Azzoni L., Alnemri E.S., Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 188:1998;2375-2380.
275. Zhong X., Schneider T.J., Cabral D.S., Donohoe T.J., Rothstein T.L. An alternatively spliced long form of Fas apoptosis inhibitory molecule (FAIM) with tissue-specific expression in the brain. Mol. Immunol. 38:2001;65-72.
276. Zhu B., Luo L., Chen Y., Paty D.W., Cynader M.S. Intrathecal Fas ligand infusion strengthens immunoprivilege of central nervous system and suppresses experimental autoimmune encephalomyelitis. J. Immunol. 169:2002;1561-1569.
277. Zipp F. Apoptosis in multiple sclerosis. Cell Tissue Res. 301:2000;163-171.
278. Zipp F., Krammer P.H., Weller M. Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol. Today. 20:1999;550-554.